With the recent approval in China of Innovent Biologics' (OTCPK:IVBIY) mazdutide as the first-ever dual GLP-1/glucagon ...

For adults with obesity and migraine, liraglutide reduces migraine burden, with reductions in mean monthly headache days and ...

Zinc glucagon, 5 mg. was given intramuscularly at 1 hour in the experiment depicted in curve "d" of Figure 2. The drug caused an improvement in the blood sugar curve, with maintenance of levels of ...

As previously reported, with no titration, DA-1726, with its novel 3:1 ratio between GLP-1R and GCGR at the 32 mg dose, demonstrated compelling maximum weight loss of -6.3% and mean weight loss of ...

We have witnessed weight loss of 13–15% with the glucagon-like peptide-1 (GLP-1) receptor agonist semaglutide and up to 18–23% with the dual GLP-1/glucose-dependent insulinotropic polypeptide (GIP) ...

Altimmune’s pemvidutide failed to significantly improve fibrosis in MASH patients in a Phase IIb study. The biotech crashed ...

GoodRx reports GLP-1 weight-loss pills are emerging, with candidates like orforglipron and oral semaglutide likely to gain ...

More than 90% of patients achieved clinically meaningful weight reduction compared to placebo in a phase 3 trial of ecnoglutide.

The oral small-molecule glucagon-like peptide-1 receptor agonist, orforglipron, reduced glycated hemoglobin (HbA1c) over 40 ...

By Dennis Thompson HealthDay ReporterTUESDAY, June 24, 2025 (HealthDay News) — A new Chinese-developed GLP-1 weight loss drug could prove a new competitor to blockbuster drugs Ozempic /Wegovy and ...

Glucagon-like peptide (GLP)-1 is an intestinally produced peptide hormone [] that stimulates insulin secretion, [] inhibits glucagon secretion, [] reduces plasma glucose levels in patients with type 2 ...

Zinc glucagon, 5 mg. was given intramuscularly at 1 hour in the experiment depicted in curve "d" of Figure 2. The drug caused an improvement in the blood sugar curve, with maintenance of levels of ...